We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Findings Explain How Tumors Guide New Blood Vessel Formation

By LabMedica International staff writers
Posted on 15 Jul 2015
Tumors must generate new blood vessels in order to grow, and a recent paper described a novel Rho-family GTPase activation cascade that was required for the generation of the endothelial cell filopodial protrusions that are necessary for the tubule remodeling that forms the lumen through which the blood will flow.

During the process of new blood vessel formation or angiogenesis, enzymes known as Rho-GTPases influence endothelial cell migration and cell-to-cell adhesion. More...
However, it is not known whether they control formation of vessel lumens, which are essential for blood flow. To clarify this point, investigators at the University of Leeds (United Kingdom) worked with mouse models that allowed them to manipulate levels of enzyme expression during VEGF (vascular endothelial growth factor)-dependent angiogenesis.

They reported in the July 1, 2015, online edition of the journal Nature Communications that lumen formation required early cytoskeletal remodeling and lateral cell–cell contacts, mediated through the RAC1 guanine nucleotide exchange factor (GEF) DOCK4 (dedicator of cytokinesis 4). DOCK family proteins contribute to cell signaling by activating G proteins of the Rho family, such as Rac and Cdc42. Dock4 dependent Rac activation regulates reorganization of the cytoskeleton and was known to lead to the formation of membrane protrusions, which are a crucial step in neuronal development and cell migration.

The investigators showed for the first time that DOCK4 signaling was necessary in angiogenesis for lateral filopodial protrusions and tubule remodeling prior to lumen formation, whereas proximal, tip filopodia persisted in the absence of DOCK4.

Senior author Dr. George Mavria, professor of medicine at the University of Leeds, said, “The finding gives an important indicator of how the protein affects the growth of secondary breast tumors in the brain. The discovery could also enable experts to predict which patients might be at risk of their breast cancer spreading, and develop drugs to prevent the growth of secondary tumors. We want to understand how these tumors form and grow, but we still need to do more research to stop these tumors growing altogether.”

Related Links:

University of Leeds 



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.